Precision BioSciences: US Patent Office Action Rejects Key Claims to CELLECTIS SA's Core Technology

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., today announced that the United States Patent and Trademark Office (PTO) granted requests filed by Precision BioSciences to reexamine two issued U.S. patents owned by the Institut Pasteur and the Universite Pierre et Marie Curie (UPMC), and licensed to Cellectis, SA (Alternext: ALCLS). In addition, the PTO rejected all 17 claims of U.S. Pat. No. 7,214,536 and 18 of 19 claims of U.S. Pat. No. 6,833,252 as obvious in view of a variety of references which had not been previously considered by the patent examiners.